Why the study?
Does ICI 141,292 exhibit cardioselective beta-adrenoceptor blocking properties compared to atenolol, propranolol, and placebo in healthy male subjects?
Does ICI 141,292 exhibit cardioselective beta-adrenoceptor blocking properties compared to atenolol, propranolol, and placebo in healthy male subjects?
ICI 141,292 demonstrates properties of a cardioselective beta-adrenoceptor antagonist with partial agonist activity in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
ICI 141,292 400 mg matches atenolol 50 mg beta-blockade in volunteers; confirms cardioselectivity with partial agonism and supports patient dosing trials.
Pringle et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: